VitaGraft Kidney
Commercial- Indications
- Kidney transplant rejection
Company intelligence / Profile preview
Oncocyte offers commercial and research-use molecular diagnostic tests for oncology and transplantation. Their portfolio includes blood-based tests for donor-derived cell-free DNA to monitor organ transplant rejection risk and a 27-gene expression assay to predict response to cancer immunotherapies. They also provide biopharma services including custom biomarker panels and next-generation sequencing support for clinical trials. Some products are commercially available while others remain in development or RUO status
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Oncocyte.